TME PHARM.CONF.IPO EO 1-

Research TME PHARM.CONF.IPO EO 1- (0N6A) on Bullrun: market cap EUR 5.91M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker0N6A
• ExchangeF
• CountryGermany
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 5.91M
• Financial periodFY2024
• Net income-EUR 5.72M
• Free cash flow-EUR 4.65M

Valuation Snapshot

latest market cap is EUR 5.91M.

About TME PHARM.CONF.IPO EO 1-

TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is mid-stage clinical development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma.

Frequently asked questions

What is TME PHARM.CONF.IPO EO 1-'s market cap?

TME PHARM.CONF.IPO EO 1-'s market capitalization is EUR 5.91M.

What does TME PHARM.CONF.IPO EO 1- do?

TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany.